Abstract
CDDP, commonly used to treat oral cancer, frequently induces adverse effects, such as severe anorexia, nausea, and emesis associated with chemotherapy. Recently, several 5-HT3receptor antagonists have developed, and among them, Granisetron hydrochrolide injection has been widely used so far. Tropisetron hydrochrolide, an oral anti-emetic reported to be as effective as parenteral anti-emetics, was launched Japan in 1998. Here, We report a comparison of the effectiveness between Kytril® infusion and Navoban® capsules, in terms of the grade of anorexia, nausea and emesis, measurement of Performance Status, and evaluation using a QOL questionnaire. Twenty oral cancer patients that received chemotherapy with CDDP and 5-FU were enrolled in the study. Our study clarified that oral anti-emetics exerted anti-anorectic, and anti-emetics effects as potently as parenteral drugs.
